Xeris Biopharma Exceeds Revenue Expectations

By Philip Seaworth • Thursday, January 08 15:13 • Permanent Link

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has announced its unaudited preliminary financial results for the fourth quarter and fiscal year 2025, indicating a record-breaking performance. The company anticipates total revenue for the full year 2025 to reach $292 million, surpassing the previously guided range of $285-$290 million and reflecting a substantial 44% growth compared to the prior year.

Specifically, Xeris Biopharma Holdings, Inc. expects fourth-quarter and full-year 2025 Recorlev® net revenue to amount to $45 million and $139 million, respectively, marking exceptional growth and outperforming expectations.

The preliminary highlights for the full year 2025 include the conclusion of the year with approximately 700 patients on Recorlev® therapy, significant revenue growth of Gvoke® by more than 13% compared to the prior year, and an expanding patient base for Keveyis® with a greater number of patients on therapy compared to the end of 2024. Additionally, the company achieved positive adjusted EBITDA in every quarter, further strengthening Xeris' intellectual property portfolio with new patents for Recorlev® and XP-8121, and presented long-term financial targets during its first analyst and investor day.

Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company focused on enhancing patient lives through its innovative products. The company's three commercially available products include Recorlev® for the treatment of endogenous Cushing's syndrome, Gvoke® for the treatment of severe hypoglycemia, and Keveyis® for primary periodic paralysis. The company also has a pipeline of development programs, with XP-8121 being a phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, in addition to multiple early-stage programs leveraging Xeris' technology platforms for its partners.

The company plans to release its full-year 2025 financial results and 2026 outlook on March 2, 2026, and is enthusiastic about the opportunities ahead, supported by its strong commercial momentum, robust balance sheet, and a clear, disciplined strategy for sustained, long-term, rapid growth across the business. The market has reacted to these announcements by moving the company's shares 2.22% to a price of $7.37. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.